{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of clinical pharmacology is the ability to interchange drugs within the same class while maintaining a consistent therapeutic effect. This practice is essential for tailoring treatment to individual patient needs, managing side effect profiles, and adapting to drug availability. This exercise  provides hands-on practice in one of the most common applications of this principle: converting doses between different glucocorticoids based on their relative anti-inflammatory potencies, a fundamental skill for safe and effective steroid therapy.",
            "id": "4917311",
            "problem": "A clinician plans to switch a patient from oral prednisone to oral dexamethasone while maintaining an equivalent glucocorticoid anti-inflammatory effect and minimizing changes in mineralocorticoid activity. Use the standard equivalence of anti-inflammatory potency relative to hydrocortisone as a well-tested pharmacologic fact: hydrocortisone $20\\,\\text{mg}$ is equipotent to prednisone $5\\,\\text{mg}$, methylprednisolone $4\\,\\text{mg}$, and dexamethasone $0.75\\,\\text{mg}$. Starting from the principle that equipotent dosing is achieved by matching total glucocorticoid effect, and that potency scales inversely with the milligram dose required to match a fixed hydrocortisone reference, derive the dexamethasone dose that produces the same glucocorticoid effect as a daily prednisone dose of $20\\,\\text{mg}$. Round your final answer to three significant figures and express the dose in $\\text{mg}$.",
            "solution": "The user wants me to solve this problem.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n-   The patient is switching from oral prednisone to oral dexamethasone.\n-   The goal is to maintain an equivalent glucocorticoid anti-inflammatory effect.\n-   Equipotent doses relative to hydrocortisone ($20\\,\\text{mg}$) are:\n    -   Prednisone: $5\\,\\text{mg}$\n    -   Dexamethasone: $0.75\\,\\text{mg}$\n    -   (Methylprednisolone $4\\,\\text{mg}$ and Hydrocortisone $20\\,\\text{mg}$ are also given but not directly needed for the conversion).\n-   Principle: Equipotent dosing is achieved by matching total glucocorticoid effect.\n-   Principle: Potency scales inversely with the milligram dose required to match a fixed reference.\n-   The starting dose of prednisone is $20\\,\\text{mg}$ daily.\n-   The task is to find the equivalent dose of dexamethasone.\n-   The final answer must be rounded to three significant figures and expressed in $\\text{mg}$.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded**: The problem is based on standard pharmacological principles of dose equivalency for corticosteroids. The provided dose ratios (prednisone $5\\,\\text{mg}$ ≈ dexamethasone $0.75\\,\\text{mg}$) are well-established and widely used in clinical practice. The concept of potency being inversely proportional to the dose required for a given effect is a fundamental principle in pharmacology. The problem is scientifically sound.\n-   **Well-Posed**: The problem is well-posed. It provides all the necessary data (initial dose, reference equipotent doses) to calculate a single, unique answer. The objective is clearly stated.\n-   **Objective**: The problem is stated using precise, objective language and standard pharmacological data. There are no subjective or ambiguous terms.\n\n**Verdict:** The problem is valid as it is scientifically grounded, well-posed, and objective. There are no contradictions, missing information, or logical flaws.\n\n**Solution Derivation**\n\nThe problem requires the calculation of an equipotent dose of dexamethasone corresponding to a given dose of prednisone. The guiding principle is that for two drugs to be equipotent, the product of their dose and relative potency must be equal.\n\nLet $P_X$ represent the glucocorticoid potency of a drug $X$, and let $D_X$ be its dose. For two drugs, prednisone ($P$) and dexamethasone ($D$), to produce an equivalent effect, the following condition must be met:\n$$ E = k \\cdot P_P \\cdot D_P = k \\cdot P_D \\cdot D_D $$\nwhere $E$ is the magnitude of the glucocorticoid effect and $k$ is a proportionality constant. This simplifies to:\n$$ P_P D_P = P_D D_D $$\n\nThe problem states that potency scales inversely with the milligram dose required to achieve a fixed effect. From the given clinical data, a dose of $D_{P, \\text{ref}} = 5\\,\\text{mg}$ of prednisone is equipotent to a dose of $D_{D, \\text{ref}} = 0.75\\,\\text{mg}$ of dexamethasone. We can use these reference doses to establish the relative potency of the two drugs.\nApplying the equipotency condition to the reference doses:\n$$ P_P \\cdot D_{P, \\text{ref}} = P_D \\cdot D_{D, \\text{ref}} $$\n$$ P_P \\cdot (5\\,\\text{mg}) = P_D \\cdot (0.75\\,\\text{mg}) $$\n\nThis equation allows us to determine the ratio of potencies, which is the inverse of the ratio of their equipotent doses:\n$$ \\frac{P_P}{P_D} = \\frac{0.75\\,\\text{mg}}{5\\,\\text{mg}} = \\frac{0.75}{5} $$\n\nNow, we need to find the dose of dexamethasone, $D_{D, \\text{equiv}}$, that is equivalent to a daily prednisone dose of $D_{P, \\text{current}} = 20\\,\\text{mg}$. We use the same equipotency relationship:\n$$ P_P \\cdot D_{P, \\text{current}} = P_D \\cdot D_{D, \\text{equiv}} $$\n\nTo solve for the equivalent dexamethasone dose $D_{D, \\text{equiv}}$, we rearrange the equation:\n$$ D_{D, \\text{equiv}} = D_{P, \\text{current}} \\cdot \\frac{P_P}{P_D} $$\n\nSubstituting the known values: the current prednisone dose ($20\\,\\text{mg}$) and the potency ratio we derived ($\\frac{0.75}{5}$):\n$$ D_{D, \\text{equiv}} = 20\\,\\text{mg} \\cdot \\frac{0.75}{5} $$\n\nNow, we perform the calculation:\n$$ D_{D, \\text{equiv}} = 20 \\cdot \\frac{0.75}{5} \\,\\text{mg} = 4 \\cdot 0.75 \\,\\text{mg} $$\n$$ D_{D, \\text{equiv}} = 3\\,\\text{mg} $$\n\nThe calculated equivalent dose is exactly $3\\,\\text{mg}$. The problem specifies that the final answer must be rounded to three significant figures. To express $3$ with three significant figures, we write it as $3.00$.\n\nTherefore, a daily prednisone dose of $20\\,\\text{mg}$ is equivalent to a daily dexamethasone dose of $3.00\\,\\text{mg}$ in terms of glucocorticoid anti-inflammatory effect.",
            "answer": "$$\n\\boxed{3.00}\n$$"
        },
        {
            "introduction": "The therapeutic effect of a drug is not determined in a vacuum; it is profoundly influenced by how the body processes it and by other concurrently administered substances. This exercise  delves into the critical area of drug-drug interactions, using the steady-state mass balance equation as a tool to quantify the impact of a potent enzyme inducer on dexamethasone's pharmacokinetics. By working through this scenario, you will develop a quantitative understanding of how changes in bioavailability ($F$) and clearance ($Cl$) necessitate precise dose adjustments to maintain therapeutic efficacy.",
            "id": "4917315",
            "problem": "A patient with severe autoimmune disease is clinically stable on oral dexamethasone, a synthetic glucocorticoid with negligible mineralocorticoid activity, dosed at $4.0$ mg every $12$ hours. The patient starts rifampin therapy for latent tuberculosis. Rifampin is a strong inducer of Cytochrome P450 (CYP) $3\\mathrm{A}4$ in both the liver and the intestine. You may assume linear pharmacokinetics, constant dosing interval, and that changes in distribution volume, protein binding, and renal function are negligible over the period considered.\n\nBefore rifampin, the apparent oral bioavailability of dexamethasone is $F_{0} = 0.80$ and the systemic clearance is $Cl_{0} = 20.0$ L/h. After rifampin induction reaches steady state, the systemic clearance increases to $Cl_{1} = 2.5 \\times Cl_{0}$ due to hepatic CYP $3\\mathrm{A}4$ upregulation, and the apparent oral bioavailability decreases to $F_{1} = 0.60$ due to increased intestinal first-pass metabolism.\n\nUsing the fundamental steady-state mass balance for linear pharmacokinetics, compute the single oral dexamethasone dose required every $12$ hours after rifampin induction to maintain the same average steady-state plasma concentration as before rifampin. Express your final dose in mg and round your answer to three significant figures.",
            "solution": "The problem statement is evaluated for validity prior to any attempt at a solution.\n\n### Step 1: Extract Givens\n-   Initial drug regimen: Dexamethasone, $D_0 = 4.0$ mg.\n-   Dosing interval: $\\tau = 12$ hours.\n-   Concomitant drug: Rifampin, a strong inducer of CYP3A4.\n-   Assumptions: Linear pharmacokinetics, constant dosing interval, negligible changes in distribution volume, protein binding, and renal function.\n-   Pharmacokinetic parameters before rifampin (state $0$):\n    -   Apparent oral bioavailability: $F_{0} = 0.80$.\n    -   Systemic clearance: $Cl_{0} = 20.0$ L/h.\n-   Pharmacokinetic parameters after rifampin induction (state $1$):\n    -   Systemic clearance: $Cl_{1} = 2.5 \\times Cl_{0}$.\n    -   Apparent oral bioavailability: $F_{1} = 0.60$.\n-   Objective: Compute the new single oral dose ($D_{1}$) required to maintain the same average steady-state plasma concentration ($\\bar{C}_{ss}$) as before rifampin.\n-   Final answer requirements: Express the dose in mg, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for scientific validity and well-posedness.\n-   **Scientifically Grounded:** The problem is based on fundamental principles of pharmacokinetics, specifically the concepts of drug clearance ($Cl$), oral bioavailability ($F$), and steady-state concentration ($\\bar{C}_{ss}$). The described drug-drug interaction between dexamethasone (a known CYP3A4 substrate) and rifampin (a potent CYP3A4 inducer) is a well-documented and clinically significant phenomenon. The induction of CYP3A4 in both the liver and intestine correctly leads to increased systemic clearance and reduced bioavailability (due to enhanced first-pass metabolism), respectively. The numerical values provided are plausible. The problem is scientifically sound.\n-   **Well-Posed:** The problem provides all necessary parameters to calculate the required new dose. The objective is clearly stated, and the assumptions (linear pharmacokinetics, constant $\\tau$) ensure that a unique and meaningful solution can be determined. The problem is self-contained and internally consistent.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, objective, and well-posed. A solution will be derived.\n\nThe fundamental principle governing the average plasma concentration of a drug at steady-state ($\\bar{C}_{ss}$) under a regimen of repeated oral dosing is given by the mass balance equation for linear pharmacokinetics. The rate of drug administration into the systemic circulation must equal the rate of drug elimination from the body. This is expressed as:\n$$\n\\bar{C}_{ss} = \\frac{\\text{Dosing Rate}}{\\text{Clearance}} = \\frac{F \\times D}{Cl \\times \\tau}\n$$\nwhere $D$ is the dose administered every dosing interval $\\tau$, $F$ is the fraction of the dose that reaches systemic circulation (apparent oral bioavailability), and $Cl$ is the total systemic clearance of the drug.\n\nThe problem requires that the average steady-state concentration before rifampin induction ($\\bar{C}_{ss, 0}$) be equal to the average steady-state concentration after rifampin induction ($\\bar{C}_{ss, 1}$).\n$$\n\\bar{C}_{ss, 0} = \\bar{C}_{ss, 1}\n$$\nUsing the steady-state formula for both conditions, we can write:\n$$\n\\frac{F_{0} \\times D_{0}}{Cl_{0} \\times \\tau} = \\frac{F_{1} \\times D_{1}}{Cl_{1} \\times \\tau}\n$$\nThe dosing interval, $\\tau$, is the same for both regimens and is a non-zero constant, so it can be canceled from both sides of the equation:\n$$\n\\frac{F_{0} \\times D_{0}}{Cl_{0}} = \\frac{F_{1} \\times D_{1}}{Cl_{1}}\n$$\nOur objective is to find the new dose, $D_{1}$. We rearrange the equation to solve for $D_{1}$:\n$$\nD_{1} = D_{0} \\times \\frac{F_{0}}{F_{1}} \\times \\frac{Cl_{1}}{Cl_{0}}\n$$\nThis equation shows that the new dose must be adjusted by a factor that accounts for the changes in both bioavailability and clearance. The change in clearance is given as a ratio, $Cl_{1} / Cl_{0} = 2.5$.\n\nWe now substitute the provided values into the derived equation:\n-   $D_{0} = 4.0$ mg\n-   $F_{0} = 0.80$\n-   $F_{1} = 0.60$\n-   $\\frac{Cl_{1}}{Cl_{0}} = 2.5$\n\nThe calculation for $D_{1}$ is as follows:\n$$\nD_{1} = 4.0 \\, \\text{mg} \\times \\left( \\frac{0.80}{0.60} \\right) \\times (2.5)\n$$\nFirst, we evaluate the ratio of the bioavailabilities:\n$$\n\\frac{0.80}{0.60} = \\frac{8}{6} = \\frac{4}{3}\n$$\nSubstituting this back into the expression for $D_{1}$:\n$$\nD_{1} = 4.0 \\, \\text{mg} \\times \\frac{4}{3} \\times 2.5\n$$\n$$\nD_{1} = 4.0 \\, \\text{mg} \\times \\frac{4}{3} \\times \\frac{5}{2}\n$$\n$$\nD_{1} = \\frac{4.0 \\times 4 \\times 5}{3 \\times 2} \\, \\text{mg} = \\frac{80.0}{6} \\, \\text{mg} = \\frac{40.0}{3} \\, \\text{mg}\n$$\n$$\nD_{1} \\approx 13.333... \\, \\text{mg}\n$$\nThe problem requires the final answer to be rounded to three significant figures.\n$$\nD_{1} = 13.3 \\, \\text{mg}\n$$\nTherefore, to maintain the same therapeutic effect, the patient's dexamethasone dose must be increased from $4.0$ mg to $13.3$ mg every $12$ hours to compensate for the enhanced metabolism caused by rifampin.",
            "answer": "$$\\boxed{13.3}$$"
        },
        {
            "introduction": "Beyond their role as therapeutic agents, drugs are powerful tools for diagnosing disease by probing physiological pathways. The adrenocorticotropic hormone (ACTH) stimulation test is a classic example, where a synthetic hormone is used to challenge the adrenal glands and assess their functional integrity. This problem  guides you through the interpretation of a clinical case, challenging you to use baseline hormone levels and the response to stimulation to differentiate between primary and secondary adrenal insufficiency, thereby connecting fundamental HPA axis physiology to diagnostic reasoning.",
            "id": "4917279",
            "problem": "A patient with suspected adrenal insufficiency undergoes a standardized high-dose synthetic adrenocorticotropic hormone (ACTH; cosyntropin) stimulation test. The hypothalamic-pituitary-adrenal axis operates by corticotropin-releasing hormone (CRH) from the hypothalamus stimulating pituitary secretion of ACTH, which in turn stimulates adrenal zona fasciculata cortisol synthesis; cortisol exerts negative feedback on both the pituitary and hypothalamus. Trophic stimulation by endogenous ACTH maintains adrenal cortical size and responsiveness.\n\nA $34$-year-old adult presents with fatigue, weight loss, orthostatic dizziness, and hyponatremia. An $08{:}00$ baseline serum cortisol is $4.0$ $\\mu$g/dL, and a simultaneous plasma ACTH is $150$ pg/mL (laboratory upper limit of normal approximately $50$ pg/mL). After intravenous administration of $250$ $\\mu$g of cosyntropin, serum cortisol is $4.8$ $\\mu$g/dL at $30$ minutes and $5.0$ $\\mu$g/dL at $60$ minutes.\n\nBased solely on first-principles physiology and pharmacology of the hypothalamic-pituitary-adrenal axis and ACTH receptor activation, which of the following interpretations is most accurate about the diagnosis and the expected cortisol increment pattern in this condition versus secondary adrenal insufficiency?\n\nA. Primary adrenal insufficiency due to intrinsic adrenal cortical failure; the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is minimal (for example, less than $7$ $\\mu$g/dL), and the absolute peak typically fails to reach at least $18$ $\\mu$g/dL; by contrast, recent-onset secondary adrenal insufficiency would show a robust increment to a normal peak.\n\nB. Primary adrenal insufficiency due to intrinsic adrenal cortical failure; the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is large (greater than $10$ $\\mu$g/dL), typically reaching an absolute peak above $18$ $\\mu$g/dL because exogenous ACTH overrides the defect.\n\nC. Secondary adrenal insufficiency of recent onset (pituitary ACTH deficiency developing over days to a few weeks); the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is minimal because the adrenals are unresponsive despite preserved size; by contrast, primary adrenal insufficiency would show a robust increment.\n\nD. Secondary adrenal insufficiency of long-standing duration (months to years) with adrenal cortical atrophy; the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is typically robust, reaching an absolute peak above $18$ $\\mu$g/dL; by contrast, primary adrenal insufficiency would show a minimal increment.",
            "solution": "The problem statement is first validated according to the specified criteria.\n\n### Step 1: Extract Givens\n- The hypothalamic-pituitary-adrenal (HPA) axis physiology is described: Corticotropin-releasing hormone (CRH) from the hypothalamus stimulates pituitary secretion of adrenocorticotropic hormone (ACTH), which stimulates adrenal cortisol synthesis. Cortisol exerts negative feedback. Endogenous ACTH provides trophic stimulation to the adrenal cortex.\n- Patient: $34$-year-old adult.\n- Symptoms: fatigue, weight loss, orthostatic dizziness, and hyponatremia.\n- Baseline morning ($08{:}00$) serum cortisol: $4.0$ $\\mu$g/dL.\n- Simultaneous plasma ACTH: $150$ pg/mL.\n- Upper limit of normal for plasma ACTH: approximately $50$ pg/mL.\n- Test: High-dose synthetic ACTH (cosyntropin) stimulation test.\n- Dose: $250$ $\\mu$g of cosyntropin, intravenous.\n- Post-stimulation serum cortisol: $4.8$ $\\mu$g/dL at $30$ minutes and $5.0$ $\\mu$g/dL at $60$ minutes.\n- Question: Based on first principles of HPA axis physiology and pharmacology, determine the most accurate interpretation regarding the diagnosis and the expected cortisol increment pattern in this condition versus secondary adrenal insufficiency.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded:** The problem is firmly rooted in established principles of endocrinology and pharmacology. The description of the HPA axis, negative feedback, the trophic role of ACTH, and the clinical presentation of adrenal insufficiency are all factually correct. The use of the high-dose ACTH stimulation test is a standard, scientifically validated diagnostic procedure. The provided laboratory values are clinically realistic for the condition in question.\n- **Well-Posed:** The problem provides a clear clinical scenario with sufficient, consistent data (biochemical and clinical) to allow for a logical deduction of the underlying pathophysiology and diagnosis. The question asks for a specific interpretation and comparison, which is answerable from the given information.\n- **Objective:** The problem is stated using precise, objective clinical and biochemical terminology. There are no subjective or ambiguous statements.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. It is scientifically sound, well-posed, and objective. A solution will be derived.\n\n### Derivation of Solution\nThe solution is derived by applying the fundamental principles of the HPA axis to the patient's data.\n\n1.  **Analysis of Baseline Laboratory Values:** The patient presents with a low baseline morning serum cortisol of $4.0$ $\\mu$g/dL. A normal morning cortisol level is substantially higher (typically $>10$ $\\mu$g/dL), so this value is indicative of adrenal insufficiency. Concurrently, the plasma ACTH level is $150$ pg/mL, which is markedly elevated above the upper limit of normal (approximately $50$ pg/mL). In a normally functioning HPA axis, low cortisol would stimulate ACTH release via negative feedback. The high ACTH level confirms that the pituitary is responding correctly to the low cortisol. The pathology must therefore lie in the adrenal gland's inability to produce cortisol despite strong stimulation from the pituitary. This combination of low cortisol and high ACTH is the defining biochemical feature of **primary adrenal insufficiency** (intrinsic adrenal gland failure).\n\n2.  **Analysis of the ACTH Stimulation Test:** The patient was administered $250$ $\\mu$g of cosyntropin (synthetic ACTH). This supraphysiological dose is intended to maximally stimulate the adrenal cortex. A normal response is a significant increase in serum cortisol, with a peak value typically exceeding $18$ $\\mu$g/dL. In this patient, the cortisol level only increased from a baseline of $4.0$ $\\mu$g/dL to a peak of $5.0$ $\\mu$g/dL at $60$ minutes. This is a minimal increment ($1.0$ $\\mu$g/dL) and the peak value is far below the normal threshold. This \"flat\" response demonstrates that the adrenal glands are incapable of synthesizing cortisol even when provided with maximal stimulation. This result confirms the diagnosis of primary adrenal insufficiency. The adrenal cortex is either destroyed (e.g., by autoimmune disease, infection, or hemorrhage) or has a congenital enzymatic defect, rendering it unresponsive.\n\n3.  **Contrast with Secondary Adrenal Insufficiency:**\n    - **Pathophysiology:** Secondary adrenal insufficiency results from deficient ACTH secretion by the pituitary gland. This leads to both low cortisol and inappropriately low or normal ACTH levels.\n    - **Response to ACTH Stimulation in Recent-Onset Secondary AI:** If the condition is of recent onset (days to a few weeks), the adrenal glands have not yet undergone significant atrophy from the lack of trophic ACTH stimulation. In this scenario, administration of exogenous ACTH (cosyntropin) will find responsive adrenal glands, resulting in a **robust** cortisol increase, often to a normal peak ($>18$ $\\mu$g/dL).\n    - **Response to ACTH Stimulation in Long-Standing Secondary AI:** If the condition is long-standing (months to years), the chronic lack of endogenous ACTH causes significant atrophy of the adrenal cortex. These atrophied glands lose their ability to respond acutely to stimulation. A standard high-dose ACTH test would show a **blunted or absent** response, similar to that seen in primary adrenal insufficiency.\n\nBased on this analysis, the patient clearly has primary adrenal insufficiency, characterized by a minimal cortisol response to high-dose ACTH. This is contrasted with recent-onset secondary adrenal insufficiency, which would be expected to show a robust response.\n\n### Evaluation of Options\n\n**A. Primary adrenal insufficiency due to intrinsic adrenal cortical failure; the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is minimal (for example, less than $7$ $\\mu$g/dL), and the absolute peak typically fails to reach at least $18$ $\\mu$g/dL; by contrast, recent-onset secondary adrenal insufficiency would show a robust increment to a normal peak.**\n- The diagnosis of primary adrenal insufficiency is correct based on the patient's high ACTH and low cortisol.\n- The description of the cortisol response in primary AI (minimal increment, peak failure to reach $>18$ $\\mu$g/dL) is the classic and correct interpretation. The patient's data (peak $5.0$ $\\mu$g/dL) perfectly aligns with this.\n- The contrast with recent-onset secondary AI (robust increment) is also physiologically correct.\n- This statement accurately summarizes the entire clinical and physiological picture.\n- **Verdict: Correct.**\n\n**B. Primary adrenal insufficiency due to intrinsic adrenal cortical failure; the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is large (greater than $10$ $\\mu$g/dL), typically reaching an absolute peak above $18$ $\\mu$g/dL because exogenous ACTH overrides the defect.**\n- The diagnosis of primary adrenal insufficiency is correct.\n- However, the description of the cortisol response is incorrect. In primary AI, the defect is intrinsic to the adrenal gland and cannot be \"overridden\" by exogenous ACTH. A large increment and normal peak describe a normal response or the response in recent-onset secondary AI.\n- **Verdict: Incorrect.**\n\n**C. Secondary adrenal insufficiency of recent onset (pituitary ACTH deficiency developing over days to a few weeks); the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is minimal because the adrenals are unresponsive despite preserved size; by contrast, primary adrenal insufficiency would show a robust increment.**\n- The diagnosis of secondary adrenal insufficiency is incorrect; the patient's ACTH is high.\n- The description of the response in recent-onset secondary AI is incorrect. Adrenals with preserved size are responsive, and the cortisol increment would be robust, not minimal.\n- The contrast statement that primary AI would show a robust increment is fundamentally false.\n- **Verdict: Incorrect.**\n\n**D. Secondary adrenal insufficiency of long-standing duration (months to years) with adrenal cortical atrophy; the expected increment in cortisol after high-dose ACTH at $30$–$60$ minutes is typically robust, reaching an absolute peak above $18$ $\\mu$g/dL; by contrast, primary adrenal insufficiency would show a minimal increment.**\n- The diagnosis of secondary adrenal insufficiency is incorrect; the patient's ACTH is high.\n- The description of the response in long-standing secondary AI is incorrect. Due to adrenal atrophy, the response is blunted or minimal, not robust.\n- While the contrast statement about primary AI showing a minimal increment is correct on its own, the main clauses of the option are factually wrong.\n- **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}